PUMA BIOTECHNOLOGY INC's ticker is PBYI and the CUSIP is 74587V107. A total of 115 filers reported holding PUMA BIOTECHNOLOGY INC in Q4 2013. The put-call ratio across all filers is 0.86 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2017 | $3,335,000 | +48.8% | 38,158 | -36.7% | 0.04% | +50.0% |
| Q1 2017 | $2,241,000 | +17.9% | 60,252 | -2.6% | 0.03% | +16.7% |
| Q4 2016 | $1,900,000 | +48.9% | 61,874 | +225.1% | 0.02% | +50.0% |
| Q3 2016 | $1,276,000 | +319.7% | 19,034 | +371.7% | 0.02% | +300.0% |
| Q3 2015 | $304,000 | -35.5% | 4,035 | 0.0% | 0.00% | -33.3% |
| Q2 2015 | $471,000 | -83.1% | 4,035 | -65.9% | 0.01% | -81.2% |
| Q1 2015 | $2,791,000 | +213.2% | 11,820 | +151.2% | 0.03% | +220.0% |
| Q4 2014 | $891,000 | -20.6% | 4,705 | 0.0% | 0.01% | -23.1% |
| Q3 2014 | $1,122,000 | +118.7% | 4,705 | -39.5% | 0.01% | +116.7% |
| Q2 2014 | $513,000 | -36.7% | 7,775 | 0.0% | 0.01% | -40.0% |
| Q1 2014 | $810,000 | -12.5% | 7,775 | -13.1% | 0.01% | -9.1% |
| Q4 2013 | $926,000 | +19.5% | 8,945 | -38.1% | 0.01% | +57.1% |
| Q3 2013 | $775,000 | +10.9% | 14,450 | -8.3% | 0.01% | 0.0% |
| Q2 2013 | $699,000 | – | 15,750 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Cormorant Asset Management, LP | 200,000 | $20,706,000 | 6.01% |
| Redmile Group, LLC | 230,673 | $23,882,000 | 2.95% |
| WEATHERBIE CAPITAL, LLC | 241,419 | $24,994,000 | 2.31% |
| Tekla Capital Management LLC | 185,820 | $19,238,000 | 2.02% |
| Ghost Tree Capital, LLC | 25,000 | $2,588,000 | 1.59% |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 5,686,668 | $588,741,000 | 1.56% |
| Iguana Healthcare Management, LLC | 25,000 | $2,588,000 | 1.48% |
| Eventide Asset Management | 42,100 | $4,359,000 | 1.34% |
| Bain Capital Public Equity Management, LLC | 401,330 | $41,550,000 | 1.17% |
| Rock Springs Capital Management LP | 31,500 | $3,261,000 | 1.16% |